Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
Forecast
National Institutes of Health plans to offer grants to small businesses. It is a forecast: the notice is expected around November 5, 2026, with applications due around January 5, 2027.
From the official notice on Grants.gov, last changed May 27, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awardsnot stated
- Total fundingnot stated
- Cost sharingNot required
- Funding typeGrant
Key dates
| Forecast posted | May 27, 2026 |
|---|---|
| Expected posting | November 5, 2026 |
| Expected deadline | January 5, 2027 |
| Expected award date | June 1, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to small businesses.
- Small businesses
Only United States small business concerns (SBCs), as defined by the Small Business Administration (SBA)(sbir.gov/apply) are eligible to submit applications for this opportunity. Individuals are eligible to serve as the PD/PI if they have never been an independent PD/PI on an NIH or CDC research, or corresponding non-NIH peer-reviewed research grant, and are a U.S. Citizen or Lawful Permanent Resident.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The National Institutes of Health (NIH), including the participating Institutes, Centers and Offices, intends to publish a Notice of Funding Opportunity (NOFO) to invite eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, and Fast-Track grant applications for the Small Business Transition Grant. Through this NOFO, NIH will support early-career scientists transitioning to entrepreneurship. In addition to funding research and development efforts at the SBC, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects, including identification of complementary industry mentors and career development resources. This NOFO will utilize the R41/R42 activity code. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this NOFO are encouraged to begin to consider applying for this new NOFO. This opportunity is available to first-time Principal Investigators, and key personnel must include a mentor with measurable effort committed to the project.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to NIH SEED (Small business Education and Entrepreneurial Development), Office of Extramural Research (OER), SEEDinfo@nih.gov, 301-827-8595.
Questions people ask
Who can apply for Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)?
National Institutes of Health accepts applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)?
Expected deadline January 5, 2027. Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience